This term sheet is for IBD and has a much higher chance of being executed than the B-OM term sheet from last year: there is no FDA verdict imperiling it.
It's disappointing that OM was not included. Like IBD, all the OM data is out, so the BP is likely just not that impressed with it. That's a shame, since whoever takes IBD should also naturally take OM. Let's see how OM shakes out, or if the company says anything in the coming weeks. They likely will, since that is a an elephant in the room.